BioNTech Agrees to Buy Scholar Rock Priority Review Voucher

Company BioNTech; Scholar Rock Event Type Priority review voucher purchase ($205 million) Modality Regulatory instrument Asset FDA priority review voucher Target Not applicable Disease Area Oncology (BioNTech late-stage portfolio) Summary Recovered source-gap item: BioNTech announced November 10 an agreement to acquire Scholar Rock’s FDA priority…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *